Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation

Table 3

Patient and tumor characteristics effect on 5-year overall and recurrence free survival.

		5 Year Overall Survival		5 Year Recurrence Free Survival
		HR (CI)	P value	HR (CI)	P value
Age		0.99 (0.96-1.03)	0.71	0.96 (0.91-1.02)	0.14
Gender	HR of Female to Male	1.19 (0.58-2.43)	0.64	0.30 (0.04-2.35)	0.25
Race	HR of other races to White, non-Hispanics	1.36 (0.68-2.73)	0.38	3.56 (1.15-11.05)	0.03
Etiology	HR HCV to non HCV	1.21 (0.58-2.54)	0.61	0.69 (0.21-2.28)	0.54
MELD		1.01 (0.97-1.05)	0.73	1.00 (0.93-1.07)	0.99
AFP	HR of >300 to ≤300	3.16 (1.40-7.15)	0.006	8.78 (2.64-29.24)	0.0004
Tumor on explant		1.38 (0.58-3.29)	0.47	2.72 (0.35-21.07)	0.34
Histological Stage	T1	1.55 (0.44-5.43)	0.50	9236	0.93
	T2	2.00 (0.59-6.61)	0.27	28440	0.93
	T3	2.08 (0.35-12.44)	0.42	82832	0.92
Histological class	Well differentiated	0.67 (0.25-1.76)	0.41	0	0.97
	Moderate or poorly differentiated	1.00 (0.47-2.14)	0.99	5.02 (0.64-39.18)	0.12
Microvascular invasion		2.36 (1.20-4.64)	0.01	4.05 (1.28-12.75)	0.02
NLR	HR of ≥5 to <5	1.75 (0.91-3.35)	0.09	1.64 (0.50-5.46)	0.42
dNLR	HR of ≥3 to <3	1.76 (0.86-3.61)	0.12	1.87 (0.51-6.92)	0.35
LMR	HR of ≥3.45 to <3.45	0.62 (0.32-1.22)	0.17	0.29 (0.06-1.34)	0.11
PLR	HR of ≥150 to <150	3.18 (1.66-6.11)	0.001	7.95 (2.52-25.09)	0.0004

AFP, alpha fetoprotein; dNLR, derived neutrophil lymphocyte ratio; HCV, hepatitis C virus; HR, hazard ratio; LMR, lymphocyte monocyte ratio; MELD, Model for End Stage Liver Disease; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio.